Nucynta ER Ruling Preserves US Status Quo On Tapentadol

 
• By Aidan Fry
  
123
Two out of three generic filers do not infringe a US patent protecting Nucynta ER until at least September 2028, the US Court of Apeeals has affirmed • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin